Losmedicamentos deorigenbiotecnológico…
89
70. Bhamidipati PK, KantarjianH, Cortes J, CornelisonAM, JabbourE.Management of imatinib-‐
resistant patientswithchronicmyeloid leukemia. TherAdvHematol
4
(2), 103-‐17(2013).
71. BrecciaM, Alimena G. Second-‐generation tyrosine kinase inhibitors as first-‐line treatment
strategy in newly diagnosed chronic phase chronic myeloid leukemia patients. Curr
CancerDrugTargets
12
(4), 391-‐401(2012).
72. Mealing S, Barcena L, Hawkins N, Clark J, Eaton V, Hirji I, et al. The relative efficacy of
imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a
systematic reviewandnetworkmeta-‐analysis. ExpHematolOncol
2
(1), 5(2013).
73. Breccia M, Salaroli A, Molica M, Alimena G. Systematic review of dasatinib in chronic
myeloid leukemia. OncoTargetsTher
6
, 257-‐65(2013).
74. Piccaluga PP, Paolini S, Bertuzzi C, De Leo A, Rosti G. First-‐line treatment of chronic
myeloid leukemiawithnilotinib: critical evaluation. JBloodMed
3
, 151-‐6(2012).
75. AwadMM, KatayamaR,McTigueM, LiuW, DengYL, BroounA, et al. AcquiredResistance to
Crizotinib fromaMutation inCD74-‐ROS1. NEngl JMed
368
(25), 2395-‐401(2013).
76. Roberts PJ. Clinical use of crizotinib for the treatment of non-‐small cell lung cancer.
Biologics
7
, 91-‐101(2013).
77. Pennell NA. Treating Anaplastic Lymphoma Kinase-‐Positive Lung Cancer in the Weeks
After the US Food and Drug Administration Approval of Crizotinib. J Oncol Pract
8
(3
Suppl), 34s-‐7s (2012).
78. Rajendra R, Jones RL, Pollack SM. Targeted treatment for advanced soft tissue sarcoma:
profileof pazopanib. OncoTargetsTher
6
, 217-‐22(2013).
79. Heudel P, Cassier P, Derbel O, Dufresne A, Meeus P, Thiesse P, et al. Pazopanib for the
treatment of soft-‐tissue sarcoma. ClinPharmacol
4
, 65-‐70(2012).
80. Harrison C, Vannucchi AM. Ruxolitinib: a potent and selective Janus kinase 1 and 2
inhibitor in patientswithmyelofibrosis. An update for clinicians. Ther Adv Hematol
3
(6),
341-‐54(2012).
81. Gu L, Su L, Chen Q, Xie J, Wu G, Yan Y, et al. Ruxolitinib for myelofibrosis. Exp Ther Med
5
(3), 927-‐931(2013).
82. CohenGS, BlackM.Multidisciplinarymanagement of hepatocellular carcinoma: amodel for
therapy. JMultidiscipHealthc
6
, 189-‐95(2013).
83. Wang Z, Wu XL, Zeng WZ, Xu GS, Xu H, Weng M, et al. Meta-‐analysis of the Efficacy of
Sorafenib forHepatocellularCarcinoma. AsianPac J CancerPrev
14
(2), 691-‐4(2013).
84. Amsberg GK, Schafhausen P. Bosutinib in the management of chronic myelogenous
leukemia. Biologics
7
, 115-‐22(2013).
85. Menaa F. Latest approved therapies for metastatic melanoma: what comes next? J Skin
Cancer
2013
, 735282(2013).
86. Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction in BRAF(V600E)
homozygousmelanomacells. Oncoimmunology
2
(1), e22890(2013).
87. VergnenègreA, Borget I, ChouaidC. Updateon the treatment of non-‐small-‐cell lung cancer:
focuson thecost-‐effectivenessof newagents. ClinicoeconOutcomesRes
5
, 137-‐41(2013).
88. Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L, et al. Gefitinib or Erlotinib as Maintenance
Therapy in Patients with Advanced Stage Non-‐Small Cell Lung Cancer: A Systematic
Review. PLoSONE
8
(3), e59314(2013).
89. Sonoda H, Mekata E, Shimizu T, Endo Y, Tani T. Safety and efficacy of panitumumab
therapy after metastatic colorectal cancer progression with cetuximab: Experience at a
single Japanese institution. Oncol Lett
5
(4), 1331-‐34(2013).
90. Muhammad S, Jiang Z, Liu Z, Kaur K, Wang X. The role of EGFR monoclonal antibodies
(MoABs) cetuximab/panitumab, andBRAF inhibitors inBRAFmutated colorectal cancer. J
GastrointestOncol
4
(1), 72-‐81(2013).
91. Niedzwiecki D, BertagnolliMM,WarrenRS, ComptonCC, KemenyNE, BensonAB3rd, et al.
Documenting the natural history of patientswith resected stage II adenocarcinoma of the
colon after random assignment to adjuvant treatment with edrecolomab or observation:
results fromCALGB9581. J ClinOncol
29
(23), 3146-‐52(2011).
92. Zhao L, He LR, Xi M, Cai MY, Shen JX, Li QQ, et al. Nimotuzumab promotes radiosensitivity
of EGFR-‐overexpressionesophageal squamous cell carcinoma cellsbyupregulating IGFBP-‐
3. J TranslMed
10
, 249(2012).
93. Perez R, Crombet T, de Leon J, Moreno E. A view on EGFR-‐targeted therapies from the
oncogene-‐addictionperspective. Front Pharmacol
4
, 53(2013).
